Drugs / clostridial enterococcus triple live tablet
clostridial enterococcus triple live tablet
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07687212 | Jul 2026 → Sep 2027 expected | heart failure | The First Affiliated Hospital of Air Force Medicial University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clostridial enterococcus triple live tablet | “Primary anti-HF therapy + Henagliflozin Proline Tablets (10mg, 1 times/day) + clostridial enterococcus triple live tablet (400mg, 3 times/day) orally, for 12 weeks.” NCT07687212 ↗ |
| Modality | Other / unclassified | “probiotic preparation” NCT07687212 ↗ |
| Route | Oral | “orally” NCT07687212 ↗ |